"Mainz Biomed partners with Quest for colorectal cancer screening test" was originally created and published by Medical ...

announced today an agreement with Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, to support commercialization of Mainz Biomed’s NextGen screening test for ...

Mainz Biomed has announced a partnership with Quest Diagnostics ... The test leverages polymerase chain reaction (PCR) technology to detect cancerous DNA in stool samples and is poised to enhance ...

Mainz Biomed’s stool-based ColoAlert test is designed to detect colorectal ... “We are excited by the opportunity to work with Quest Diagnostics,” commented Guido Baechler, Chief Executive ...

announced today an agreement with Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, to support commercialization of Mainz Biomed’s NextGen screening test for ...